Mark Erlander, PhD
Chief Executive Officer
Dr. Erlander has served as our Chief Executive Officer since May 2020 and formerly as the Chief Scientific Officer from March 2013 to May 2020. Previously, he was Chief Scientific Officer at bioTheranostics, a subsidiary of bioMérieux, a molecular diagnostic testing company focused on clinical applications in oncology, where he served from 2008 to 2013. From 2000 to 2008, Dr. Erlander was Chief Scientific Officer at Arcturus, Inc. (later AviaraDx), which was acquired by bioMérieux in 2008. Dr. Erlander entered therapeutics as a Group Leader and then Research Fellow in drug discovery at Johnson & Johnson from 1994 to 2000. From 1991 to 1994, Dr. Erlander was a Postdoctoral Fellow and then Assistant Professor at Scripps Research. He has 44 issued patents, over 50 pending applications, and has co-authored more than 90 scientific publications. Dr. Erlander holds a B.S. in Biochemistry from the University of California, Davis, an M.S. degree in Biochemistry from Iowa State University, and a Ph.D. in Neuroscience from the University of California, Los Angeles.
Chief Financial Officer
Mr. Levine has served as Chief Financial Officer since 2021. Mr. Levine has extensive corporate and investment banking experience with both private and public biotechnology and pharmaceutical companies. Prior to joining Cardiff Oncology, Mr. Levine served as CFO of Cidara Therapeutics, where he led the financial aspects of important pre-clinical and clinical collaborations with Janssen Pharmaceuticals (part of Johnson & Johnson) and Mundipharma with a combined value of over $1.3 billion. Previously, Mr. Levine was the president and chief executive officer of Sapphire Energy Inc., a private industrial biotechnology company that was sold to two private investor groups. He also previously served in the same roles at Verenium Corp., where he negotiated six product commercialization partnerships and asset sales, before selling the company to BASF. He also previously was a managing director in the investment banking division of Goldman Sachs & Co., serving in its healthcare and energy groups.
Mr. Levine earned an MBA in finance from the Wharton School of the University of Pennsylvania and a BA in economics from Brandeis University.
Chief Operating Officer
Vicki Kelemen has served as Chief Operating Officer since 2020, and previously as Vice President of Clinical Development and Investor Relations since 2018, and Vice President of Corporate Communications from 2017 to 2018 and Senior Director of Marketing Communications from 2015 to 2017.
Prior to joining Cardiff Oncology (formerly Trovagene), Ms. Kelemen was Sr. Vice President at a global healthcare communications agency, where she specialized in the market development and commercialization of therapeutics for serious and rare diseases, as well as the development of patient advocacy programs. Previously, Ms. Kelemen held progressive operations, marketing and communications management and executive positions and lead the development and launch of several novel products with pharma/biotech companies focused in therapeutics, including Amylin, Maxim, Agouron (Pfizer), Valeant, Ardea Biosciences (Astra Zeneca) and Dura Pharmaceuticals. Ms. Kelemen began her career in healthcare with Bayer Pharmaceuticals, where she held positions is sales, sales training, and marketing.
Ms. Kelemen has a BS degree in pre-med and medical anthropology from the University of California at Davis.
Tod Smeal, PhD
Chief Scientific Officer
Dr. Smeal has served as Chief Scientific Officer since January 2022. Previously he was CSO at Hexagon Bio (2020-2021), CSO of Cancer Biology at Eli Lilly and Company (2015-2020), Director at the Oncology Research Unit of Pfizer (2003-2015), and Senior Group Leader at the SUGEN site of Pharmacia and Upjohn and SUGEN (1998-2003). When Pfizer closed the SUGEN site in 2003, Dr. Smeal continued his oncology research efforts on targeted therapies and their resistance mechanisms with Pfizer at their San Diego oncology research site. Subsequently in 2015, Dr. Smeal joined Eli Lilly where he led their oncology research efforts at Lilly Research Labs in Indianapolis. During his over 20 years in industry working on targeted therapies, Dr. Smeal has played key leadership roles in delivering about 20 FHD/NMEs and several FDA approved or soon to be approved drugs (e.g., Lorbrena, Xalkori, Vizimpro and Nirogacestat). Dr. Smeal’s work in developing cancer therapies has been focused on intracellular signaling, kinases, drug pharmacology, and targeted therapies and their resistance mechanisms. He has over 45 publications which includes high impact publications in Cell, Nature, New England Journal of Medicine, Cancer Cell and Cancer Discovery.
From 1994 to 1998, Dr. Smeal was a post-doctoral fellow of the American Cancer Society and a senior post-doctoral fellow of the MIT-Merck fellowship program. Dr. Smeal holds a B.S. in Biology from the Massachusetts Institute of Technology and a Ph.D. in Biology from the University of California, San Diego.
Brigitte Lindsay has served as Vice President of Finance and Corporate Secretary since 2019 and previously as Controller from 2012 to 2019. She brings extensive biotech experience to the company having previously served as Controller for AviaraDx both before and after acquisition by bioMérieux. Prior to AviaraDx, she was Manager of Financial Reporting and Analysis at publicly traded Carl Zeiss Meditec which is majority owned by the global bioscience optics leader Carl Zeiss AG. Ms. Lindsay has held progressively increasing finance and accounting positions at other leading companies including Philips-Respironics. She adds a global finance perspective having worked for multinational corporations and in both the US and Germany.
Ms. Lindsay received her Diplom Betriebswirt from the Verwaltungs und Wirtsschafts Akademie in Munich, Germany.
Charles Monahan, RPH
SVP Regulatory Affairs
Mr. Monahan has served as Sr. Vice President of Regulatory Affairs since 2021. Mr. Monahan is a registered pharmacist with extensive experience in clinical pharmacy, healthcare management, and pharmaceutical development. He has over 20 years of regulatory experience developing drugs and biologics for oncology, infectious diseases, and ocular indications.
Most recently, Mr. Monahan served as the Global Head of Regulatory Affairs for Erytech PharmaSA where he led the regulatory strategy and execution of the company’s lead asset across multiple oncology indications in both the United States and Europe. Prior to Erytech, Mr. Monahan held senior regulatory positions at several pharmaceutical companies including Millennium Pharmaceuticals, Molecular Insight Pharmaceuticals, AVEO Pharmaceuticals, and Transgene SA covering all stages of development, preclinical through post-commercialization.
Mr. Monahan earned his BS in Pharmacy from the University of Rhode Island and a MS in Regulatory Affairs and Health Policy from the Massachusetts College of Pharmacy and Health Sciences.